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The “curative medical model” dominates medical 
decision-making, but in patients with advanced 
lung disease it can be redundant and even harmful. 
Clinicians are reluctant to abandon the traditional 
approach. However, a steady sea-change is under 
way not just for potentially life-limiting respiratory 
disease but also for other long-term conditions, 
such as heart failure. The sea-change is welcome, 
but it has been slow in coming for reasons that are 
complex and entrenched.
The burden of disease arising from lung cancer 
is well known and health services directed towards 
palliative care for patients with lung cancer are usually 
available. However, despite increasing mortality due 
to chronic obstructive pulmonary disease (COPD) and 
interstitial lung disease (ILD), the provision of end-of-
life care for these conditions is limited. For example, 
in a recent Swedish study, Ahmadi et al. [1] reported 
that 75% of patients with oxygen-dependent ILD 
had breathlessness (not surprisingly), but only 17% 
of them had their symptoms controlled. By contrast, 
42% of patients with lung cancer had significant 
breathlessness, of whom 33% experienced symptom 
control. The same discrepancies exist between lung 
cancer and COPD [2].
Why is this? Why is the effective management of 
similar degrees of physical and emotional suffering 
based on their pathogenesis rather than their 
impact? This is not just a question of unmet need. 
It is a question of inequity, sometimes amounting 
to neglect, with its origins in societal as well as 
professional attitudes and behaviours [3].
In this article, I wish to focus on issues that 
often stand in the way of making palliative care 
accessible to the significant number of patients 
with respiratory disease who need it [4]. These 
include the pre-eminence of the curative medical 
model and in turn, our reluctance to engage in 
prognostic conversations and advance care 
planning.
The curative medical model
My personal perspectives on this theme have 
been strengthened recently by conducting over 
140 one-to-one coaching sessions for consultant 
physicians and surgeons across three hospitals 
in Scotland. The primary aim of these sessions 
has been to address the widespread problem of 
treatment overuse leading to harms and waste 
[5, 6]. One of the drivers is the dominance of 
the curative medical model in medical decision-
making. It is at the core of the health system and 
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paradoxically works against appropriate good care 
at the end of life.
The power of curative intent has complex origins. 
There is the death taboo and the “drive to survive” 
recently highlighted in “Being Mortal” by Atul 
Gawande [7]. We do everything to cling on to life and 
shrink from letting go even when death is inevitable. 
For doctors, saving lives can be heroic and death 
means failure. Over-treatment is incentivised by 
the perception that the risks of omission are greater 
than the risks of commission. Societal addiction to 
the curative model is also (not so) subtly reinforced 
by financial incentives and political agendas [6].
A range of cognitive biases provide doctors with 
moral justification for treatment overuse [8]. We 
are therefore slow to avoid or at least minimise 
what may be futile, burdensome or contrary to 
the patient’s wishes. We hide behind uncertainty 
and “give the patient the benefit of the doubt”. 
This means that nonbeneficial treatments are 
widespread in the last 12 months of life [4].
Every treatment has the potential to cause harm, 
and towards the end of life the balance between 
benefits and harms shifts steadily (figure 1). Yet 
somehow in the death-denying, death-defying 
environment of modern medicine, the principle of 
“primum non nocere” (first do no harm) has got lost. 
It should therefore come as no surprise that in one 
study, quality of life (and death) during terminal 
illness was inversely proportional to the complexity 
and cost of medical interventions [9].
Persistence with what is futile also denies 
patients appropriate palliative care (treatment 
underuse). Why do we regard palliative care 
as second best? This is simply not true. In a 
landmark study, patients with stage 4 lung cancer 
who received well-organised palliative care had 
improved outcomes compared with those who 
received ongoing “curative” treatment, including 
survival [10]. A similar pattern of outcomes has 
been observed with nonmalignant respiratory 
disease [11].
COPD and ILD
All of these considerations are relevant, as well as 
problematic, in our current approach to advanced 
COPD and ILD (notably idiopathic pulmonary fibrosis 
(IPF)). In COPD, post-hospital-discharge “care 
bundles” focus almost exclusively on preventing 
further exacerbations with little mention of 
palliative care [12]. For IPF, the advent of anti-
fibrotic treatments raises significant issues because 
they represent the attempt to cure. Although these 
treatments slow disease progression, and this is 
a legitimate aim, median survival increases from 
∼2.9 years [13] by only about 2.5 years [14]. This 
is not a cure. Even if treatment is successful, the 
need for palliative treatments is only deferred and 
should be anticipated. Yet guidelines may [15, 16] 
or may not [17] give attention to this need.
Prognostic conversations
The question is: how do we overcome the problems 
I have highlighted? When the system in which I 
function is so orientated towards “fix it” medicine, 
what options do I have? My conclusion is that 
modifying service priorities towards better end-
of-life care only gains traction when individual 
clinicians choose to set aside the curative medical 
model as the arbiter of best practice. My contract 
with a patient means providing for their care 
irrespective of the potential for improved or 
stabilised organ function even though that is still 
a legitimate aim.
The starting point is honesty about prognosis. 
Mortality following a patient’s first admission 
with acute respiratory failure due to COPD was 
28% at 1 year and 48% at 2 years in one study 
[18]. In another, the median survival for patients 
experiencing an acute exacerbation of ILD was 
15.5 months from diagnosis and only 2.2 months 
following the acute exacerbation itself [19]. 
Yet patients with COPD and ILD rarely have a 
conversation with their clinician that takes these 
facts into account [20, 21]. Is it therefore any 
surprise that providing for their end-of-life needs 
is delayed or altogether neglected?
There are a number of myths and misconceptions 
about prognostic conversations that need to be 
dispelled.
1) A prognostic conversation is not necessarily 
the same as an end-of-life conversation, although 
obviously the two may overlap. I prefer the former 
term because a prognostic conversation is relevant 
at any stage in a patient’s illness trajectory, including 
at the time of diagnosis.
2) The word prognosis is popularly understood 
to mean “how long have I got?”. However, 
notwithstanding the need to consider survival 
prospects, it is more relevant to think of prognosis 
in terms of quality rather than quantity. A prognostic 
conversation means asking “what does the future 
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Figure 1 The value of a medical intervention (x-axis) in relation to the diminishing potential 
for benefit from a “curative” medical intervention that is offered during the last days/weeks/
months of life. Note the unchanging probability and magnitude of harm. First created by Avedis 
Donabedian (1919–2000). Reproduced from [38] with permission.
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disease on future quality of life. When someone’s 
health status is deteriorating, considering “what 
does the future hold?” is a needful prerequisite for 
improved care.
3) A prognostic conversation based on “what 
does the future hold?” also accommodates 
uncertainty with greater ease. Uncertainty is 
something that we all need to own. William Osler 
said: “Medicine is a science of uncertainty and an 
art of probability”. Smith et al. [22] have set out 
three principles for managing uncertainty: first, 
normalise it; second, allow the emotions associated 
with uncertainty to be processed; and third, help 
patients to live in the here and now more than in 
the future.
4) The majority of patients and their families 
prefer to have a prognostic conversation, but expect 
the clinician to initiate it [23]. For the minority who 
prefer otherwise, it is not difficult to ask “are you 
the sort of person who would like to talk about 
what might lie ahead?” and to respect their answer. 
Some patients prefer not to have a prognostic 
conversation, but that is not a reason for denying 
it to everyone.
5) It is often said that prognostic conversations 
will adversely affect patient morale, including loss of 
hope. The evidence suggests differently: a patient’s 
hope is not tied exclusively to survival [24, 25]. Hope 
is a complex mix of anticipatory perspectives that is 
about much more than survival. The avoidance of 
truth telling can be just as damaging to hope – by 
creating the impression that the future cannot be 
mentioned! On balance, it is better to disclose the 
truth rather than withhold it.
Practicalities
In the context of a busy medical unit, time 
constraints often mean that a prognostic 
conversation is difficult. But it is still possible even 
when time is limited. This is not to advocate poor 
quality communication, but rather to encourage 
it to happen!
My personal approach is to ask a patient to 
reflect on the trends in their health status: “How 
have things been going for you in the past few 
months?”; “Compared with 6 months ago, do 
you think things have changed?” Reflection can 
then become the basis for anticipation – thinking 
that explores treatment goals and choices on the 
assumption that established trends will continue 
albeit at a variable pace. If the patient lacks capacity, 
then a similar approach can be used when talking 
to family members.
For a patient with severe COPD or ILD, the 
prospect of dying generates not just existential fear, 
but also the fear of uncontrollable symptoms. For 
some patients and their families, discussing the 
mode of dying (often carbon dioxide narcosis) and 
assuring them that the control of severe dyspnoea 
will be a treatment priority, provides important 
reassurance.
Advanced training in communication skills 
provides for additional benefits [26]. For more on 
this topic, I recommend the article by Ragland et 
al. [27] and the film “A Good Death” [28].
Advance care planning
In an age when dying is a process more often 
than it is a single event, human experience at the 
end of life often involves an intensifying sense of 
powerlessness [29]. The time to die is a time when 
control over my fate is finally ceded. It is in this 
context that deliberate steps to preserve a person’s 
ability to feel in control provide a meaningful 
contribution to their well-being. This is one of the 
reasons for creating an advance care plan (ACP) 
(table 1). Things go better with planning. In a 
landmark study, Detering et al. [30] highlighted 
that whereas 86% of patients with an ACP had their 
wishes and choices fulfilled at the end of life, this 
was true for only 30% of patients who did not have 
an ACP.
However, if I am an advocate for ACPs then, with 
others, I also recognise that implementation is not 
easy [31, 32]. I am therefore selective (table 2). 
My particular concern is to try to ensure quality 
of care during episodes of acute deterioration 
(acute exacerbation of COPD and acute 
exacerbation of ILD). Such events are common 
and distressing, and may be terminal. Too often 
patients experience unnecessary physical and 
psychological harm resulting from discontinuity of 
care and well-meaning, but inappropriate, medical 
interventions [34]. Advance care planning including 
Table 1 Items for inclusion in an advance care plan
Preferred place of death
Appointment of health/welfare power of attorney
Care arrangements if/when dependent
Will and funeral arrangements
Future crisis management: treatment escalation/limitation boundaries in the 
event of acute deterioration
Do not resuscitate preference
Information about how and when to use palliative treatments (e.g. opioids, 
benzodiazepines, “Just in case” prescribing)
End-of-life goals: spiritual, relational (“What matters to me?”; the bucket list)
Table 2 Triggers for initiating an ACP for patients with COPD or ILD
Has had 1 or more admission with acute respiratory failure
Has reached a significant milestone (e.g. commenced long-term oxygen 
therapy, moved to a care home)
Is initiating health/welfare power of attorney
Is exhibiting rapidly progressive function decline [33]
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treatment escalation/limitation plans address 
these issues.
The entry point for advance care planning is the 
prognostic conversation [35]. However, although 
conversations at the time of acute events are 
critically important, hospitalisation is not the best 
time for initiating an ACP [36]. The best place 
is the outpatient clinic. Incorporating an ACP 
into the educational objectives for a pulmonary 
rehabilitation programme may be helpful [37].
Conclusion
Improving quality of care for patients with advanced 
COPD, ILD or any other progressive respiratory 
disease requires a paradigm shift. Best supportive 
care as it is currently experienced is far from best. 
Palliative care needs to sit alongside curative 
intent as an equally legitimate professional goal. 
For individual clinicians, the key is to engage in 
prognostic conversations not as “breaking bad 
news”, but as a normative element in patient 
assessment. The question “What does the future 
hold?” opens the gateway to shared decision 
making, advance care planning and timely palliative 
care. These should be at the core of professional 
training, service provision and management 
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